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 ■ INTRODUCTION
Osteoarthritis (OA) or osteoarthrosis is a low-grade, progressive 
inflammatory disease that may entail joint degeneration (1) that 
affects all joint structures, notably the cartilage of synovial joints. 
OA evolves into joint insufficiency, characterized by changes in 
articular cartilage, with fibrillation and fissure zones, microfractures, 
cysts, subchondral sclerosis and formation of osteophytes on joint 
edges. These changes lead to chronic pain and functional constraints 
of the affected joints, in addition to the physical and psychological 
sequelae that often manifest in individuals with OA, causing greatly 
reduced quality of life.
OA is the most common joint disease (2,3) and affects mainly 
the knees, hips, hands and feet. In the USA, it is estimated that 
36.4% of individuals over 60 years old have OA in their knees 
(4). This disease of great medical and economic importance is 
responsible for the inability to perform labor in approximately 15% 
of the adult population of the world. In Brazil, OA is currently the 
third most common disease of those who are insured for Social 
Security and receiving disease aid, corresponding to 65% of the 
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cause of disability (5). The data are more relevant if we consider 
that the population of individuals older than 60 years, which was 
19 million in 2012, will increase to more than 64 million in 2050 
according to the Brazilian Institute of Geography and Statistics 
(IBGE) (6). These are extremely relevant data, considering the 
inability to work, reduced quality of life and costs to the health 
system generated by OA, including treating the disease and early 
retirement due to functional disability (7).
Until a few decades ago, the treatment of OA was limited to 
the use of simple analgesics, anti-inflammatory medications, 
physical measurements, steroid injections and, in refractory cases, 
surgical treatment. Understanding the pathophysiology of OA, that 
the pathogenesis is not purely mechanical and/or related only to 
aging, as well as the inflammatory pathways involved, has led to 
the clinical application of several novel treatments (8). These new 
treatments have significantly altered the clinical and therapeutic 
approach to OA.
This study aims to update our understanding of the disease 
in our country, to establish a general overview of OA, to suggest 
epidemiological indicators and to identify forms of treatment 
undertaken in Brazil. For this reason, a scientific advisory committee 
(SAC) was convened, consisting of specialists in the three areas 
directly involved in the detection, diagnosis and treatment of OA, 
namely, physiatry, orthopedics and rheumatology. These experts, in 
turn, included a total of 21 doctors in the most important regions of 
the country with remarkable knowledge about OA and composed 
the Delphi panel, from which the data presented here were obtained.
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 ■ MATERIALS AND METHOD
Initial discussions of the SAC led to the elaboration of a 
data collection form that, to fulfill the main objective, was used 
for the following goals: a) to capture epidemiological indicators 
of OA and b) to identify the use of different forms of treatment 
according to the affected joint and radiological of Kellgren and 
Lawrence classification. The questionnaire was then sent to the 
experts, including 8 physiatrists, 7 orthopedic surgeons and 6 
rheumatologists.
Delphi technique
This technique originated in 1966 (9) and is currently, to a 
large extent, used and intended for the deduction and refinement 
of opinions of a group of experts or specially educated individuals, 
with the objective of achieving a consensus of opinion by means of 
questions, feedback and review of responses.
The technique is defined as a “systematized method of 
information judgement” and is used to obtain expert consensus of 
a given theme through jointly phased or cycle-based validation. 
The Delphi technique is based on the structured use of the 
knowledge, experience and creativity of a panel of specialists, 
assuming that collective judgment, when organized, is better 
than the opinion of a single individual or of groups devoid of 
specific knowledge (9).
Obtaining consensus
More than 28,000 data items were raised in the first wave of 
questionnaires collected. As a reflection of the homogeneity of 
the chosen panel, slightly more than 1% of the data points were 
classified as revisions (considered “outliers”). Of these, almost 
half have not been revised because they were not outliers when 
considering the averages in each subgroup (different specialties), 
signaling a typical difference in the subgroup and not a real outlier. 
In such cases, the global data were disregarded to demonstrate 
differences by specialty.
In the few remaining cases, one group was reviewed and 
another, due to a panel member not being able to review, was 
treated as “missing data” and handled with “pairwise” deletion, 
leading to the consensus (understood as the average near the 
median) presented below.
 ■ RESULTS
Epidemiology
OA had a prevalence of 33% in Brazil. That is, one-third of the 
individuals in the reference population (individuals over 25 years 
of age) had OA. Considering this prevalence, one can estimate 
that presently, the total number of Brazilians with OA is almost 
40 million (Figure 1).
Other epidemiological data are shown in Table 1.
In the population evaluated, the gender distribution of Brazilians 
with OA is 40.2% men and 59.8% women, indicating a proportion 
of 1.5 women to each man.
As for the age range, the distribution was 63.7%, 26.8% and 9.5% 
in the age groups >60 years, 41-60 years and <40 years, respectively.
Cases of OA with a pathogenesis linked to biomechanics 
represented little more than 1/3 of all patients. The cases arising 
from genetics constituted the second largest group, representing 
approximately 1/5 of the patients.
In relation to the distribution of patients according to body 
mass index (BMI), 46% of the patients were obese (BMI >30.0). 
Those who were overweight (BMI 25.0-29.9) represented just over 
30% of the OA patients. In summary, the portion of patients above 
normal weight represented more than 3/4 of all patients.
According to the Delphi panel, almost half of the patients are 
sedentary. The regular practice of nonprofessional physical activity 
occurs in approximately 1/4 of the patients. A very similar result 
was found regarding the practice of professional physical activity.
Clinical profile of patients according to the joints 
affected
Considering all individuals with OA, 45% had knee joint 
involvement. Cases involving the hand joints comprised the second 
largest group, while those affecting the hip represented less than 
20% of patients.
The sum of the percentages reached 112.4%, signaling that just 
over 12% of the patients had more than one joint compromised.
Figure 1 - Prevalence of osteoarthritis in Brazil.
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Clinical profile of patients by the presence of renal, 
gastrointestinal and cardiovascular risks
The presence of increased renal risk was found in approximately 
1/5 of patients, while increased cardiovascular risk was found in 
29% of patients. Increased gastrointestinal risk occurred in 27% 
of patients. 
Forms of treatment
The following are the findings for the forms of treatment 
undertaken by different specialists in OA of the knee, as determined 
by the SAC. The findings pertaining to the other affected joints are 
the subject of future research.
No form of treatment
The findings related to “no form of knee OA treatment” reported 
by the Delphi panel varied largely, not only among the specialties 
but also according to the clinical condition of the patients. The 
rheumatologists established at least one form of treatment for 
patients with knee OA, regardless of the grade of radiographic 
Kellgren & Lawrence classification. Orthopedic surgeons are 
especially involved with treating patients who have degrees III and 
IV of OA. For physiatrists, intervention increases with the severity 
of the disease and was greater than the orthopedic approach and less 
than the rheumatological approach at all stages (Figure 2).
Nonpharmacological treatment
For nonpharmacological treatment, a hypocaloric diet was 
recommended by all three types of specialists and was similar for 
varying degrees of involvement, especially for the most pronounced 
forms of the disease. Notably, the rheumatologists started the diet 
in more than 40% of patients at the earliest stage of the disease 
(Figure 2).
The same behavior pattern was found with the indications for 
physiotherapy (Figure 2).
The results still show that acupuncture is also a therapeutic 
modality indicated mainly by physiatrists for all degrees of the 
disease. This modality, however, is less adopted both by orthopedists 
and rheumatologists, with the latter using acupuncture in less than 
30% of the patients with radiographic grade IV OA (Figure 2).
Figure 2 – Nonpharmacological treatments of OA in Brazil among specialties
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Table 1 - Epidemiological data (%) for OA in Brazil.
Gender male=40.2       female=59.8
Age 63.7 (>60 years) 26.8 (41-60 years) 9.5 (<40 years)
Causes
36.0 (genetics)
20.0 (biomechanics)
16.7 (posttraumatic)
15.6 (inflammatory)
11.8 (unidentified)
BMI 46.0 (>30.0) 31.7 (25.0-29.9) 14.6 (18.5-24.9) 7.8 (<18.5)
Physical activity
48.3 (sedentary) 26.2 (professional practice) 25.5 
(nonprofessional practice)
Affected joints 45 (knees) 31.4 (hands) 18.6 (hip) 17.4 (others)
Risk of diseases 29.0 (cardiovascular) 27.1 (gastrointestinal) 19.3 (renal)
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Pharmacological treatment
Oral nonsteroidal anti-inflammatory drugs (NSAIDs)
The prescription use of NSAIDs is seen in three specialties 
at all stages of knee OA, and in the more advanced stages of the 
disease (stages III and IV), approximately 54% of patients receive 
NSAIDs prescribed by all three types of specialists (Figure 3).
Oral pharmacological treatment with nonselective 
NSAIDs in fixed combination with a coater
The level of prescription of this class of treatments is lower than 
that of the isolated form of NSAIDs, except among rheumatologists 
who prescribed the fixed combination with the gastric protector for 
slightly more than 40% of the knee OA patients in the most severe 
OA class.
Oral pharmacological treatment with selective NSAIDs 
for COX-2
Orthopedic surgeons maintain higher levels (20%) of using 
these agents for their OA patients, especially in the more advanced 
degrees of the disease. Physiatrists and rheumatologists restrict the 
use of this class in patients with OA (Figure 3).
Oral pharmacological treatment with symptomatic 
slow-acting drugs for osteoarthritis (SYSADOA)
As for oral pharmacological treatment with SYSADOA, the 
rheumatologists prescribe them to approximately 30% of individuals 
with the initial forms of OA pathology and for half or more of the 
patients in the most advanced stages of the disease. Physiatrists 
and orthopedic surgeons prescribe in a very similar way at all 
stages, increasing progressively from the first to the third phase and 
decreasing in phase IV, when OA is more serious (Figure 3).
When the question was more directed, asking the specialists to 
opt for isolated glucosamine, glucosamine + chondroitin, diacerein 
or soy and avocado proteins, the most used among the 3 specialties 
was glucosamine + chondroitin, followed by isolated glucosamine 
for physiatrists and orthopedic surgeons (Figure 4).
Oral pharmacological treatment with serotonin 
reuptake inhibitors and/or norepinephrine
Regarding the prescription of serotonin reuptake inhibitors and/
or norepinephrine, orthopedic surgeons are the ones who use this 
class of drugs the least. Physiatrists prescribe them more frequently 
for knee OA, while rheumatologists indicate this therapy for the 
most advanced forms of OA.
Oral pharmacological treatment with opioids
The rheumatologists use these agents with more than 40% of 
the patients with knee OA in the most severe phase of the disease. 
Physiatrists also prescribe them, followed by orthopedic surgeons.
Articular pharmacological treatment with corticosteroids
The greatest use of corticosteroids was by rheumatologists. The 
physiatrists are the experts who use them the least.
Articular pharmacological treatment with hyaluronic 
acid
The rheumatologists indicated hyaluronic acid treatment more 
frequently for grade III than for degree IV knee OA. Orthopedic 
surgeons indicated the application of intraarticular injections in 
Figure 3 – Pharmacological treatment among specialties
25.0
17.9
5.0
30.0
21.4
13.3
34.4
25.7
20.0
30.0 28.6
23.3
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Physiatrists Orthopedists Reumathologists
Oral nonselecve NSAIDs treatment
Grade I Grade II Grade III Grade IV
15.6
21.6
30.032.5
34.3
46.7
38.8 40.0
55.0
31.3 32.1
60.0
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Physiatrists Orthopedists Reumathologists
ORAL SYSADOA
Grade I Grade II Grade III Grade IV
15.3
28.7
5.0
15.3
31.6
10.0
15.0
30.7
13.315.0
28.6
17.5
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
Physiatrists Orthopedists Rheumatologists
Treatment with COX-2 Selecve NSAIDs
Grade I Grade II Grade III Grade IV
5Epidemiology of osteoarthritis in Brazil
Coimbra IB et al.
CLINICS 2019;74:e722
approximately 30% of patients with degree III and in 22% of those 
with degree IV knee OA. The physiatrists use it for approximately 
10% of patients with OA of knee grades II, III and IV.
Surgical treatment
The data show that most of the patients who are referred for 
surgical procedures by the three types of specialists involved are 
diagnosed with grade IV knee OA.
 ■ DISCUSSION
This study traced a comprehensive study of the epidemiological 
profile of OA in Brazil, including prevalence information, risk 
factors and options for treatment of the disease, through the 
consensus opinion of 21 specialists in the areas of rheumatology, 
physiatry and orthopedics. We used the Delphi approach, which 
provides a transparent, explicit and extensive method for the 
closest possible identification of the current reality of OA in 
our country. The use of this technique is intended for situations 
characterized by the absence of data, lack of historical data, 
necessity of an interdisciplinary approach or for the generation 
of new ideas. The Delphi method also aims to predict future 
trends of the subject under study in the sense of extracting the 
structural perspectives.
The results presented herein reflect the consensual practice of 
specialists from different Brazilian regions in relation to treatment 
approaches for patients with symptomatic knee OA. The results 
thus provide robust evidence regarding the prevalence of OA and 
the treatment options.
We found that OA had a prevalence of 33% in the Brazilian 
adult population. The epidemiological studies available indicate 
that OA affects 10-15% of the world’s population, presenting an 
incidence of more than 60% of men and 70% of women over 65 
years of age (10). Regarding the prevalence, OA increases with 
age and is unusual in individuals under 40 but more frequent 
after the age of 60 (11). Our data match the worldwide findings. 
The precariousness of radiographic examinations for the early 
diagnosis of OA is also highlighted because radiography only 
presents changes after the disease has irreversibly compromised 
the tissues, especially cartilage. This fact recently led to the 
European League of Associations of Rheumatology (EULAR) 
to recommend that for clinical signs suggestive of OA, radiographic 
examination is not necessary to initiate treatment (12). Among 
joint diseases, OA is the most common, and it is estimated that 
one third of adult individuals between 25 and 74 years old present 
radiological evidence of OA in at least one joint (2). That study 
reinforces the findings found in the present research.
We also found a 1.5:1 ratio of women to men with OA. This 
result is in accordance with those of Lawrence et al. (2) who showed 
that the incidence of OA in the hand, hip, and knee increases with 
age, and women have higher incidence rates than men do, especially 
after the age of 50 years, possibly due to the hormonal imbalance 
that strikes women in the most advanced stages of adult life. Obesity 
is also a strong risk factor for the development of OA. Data show 
that OA is associated with metabolic syndrome, which implies a 
common pathogenic mechanism involving metabolic abnormalities 
and systemic inflammation (13-16). In studies using NHANES III 
data, there was a 5.26-fold increased risk of metabolic syndrome in 
individuals with OA at the age of 43.8 years (17-19). The present 
study found that 46% of the patients are obese, with a BMI above 
30.0. Those who were overweight (BMI 25.0-29.9) represent a few 
more than 30% of the patients. Together, both groups represent 3/4 
of all OA patients.
The objectives of OA treatment include pain relief and 
functional improvement (20).
In clinical practice, treatment should be based on individual 
evaluation, taking into account their needs and preferences, or 
the subjective interpretation of the evidence by the doctor (21). 
A gold standard treatment does not yet exist according to medical 
societies that most often deal with OA. Most likely due to the 
different phenotypes, OA in different joints is also treated different. 
Indications for knees are not the same as those for the spinal column 
or hand joints.
OA treatment can be divided into nonpharmacological, 
pharmacological and surgical interventions, the latest for the most 
severe cases. More than 90% of orthopedic surgeons report that they 
do not prescribe any treatment for Kellgren & Lawrence grades I 
and II OA. This result can be explained by the specialty profile 
because orthopedic surgeons are requested for more severe cases 
for surgical treatment. Alternatively, rheumatologists will initiate at 
least one type of treatment in all grades of OA.
Nonpharmacological measures include patient education, the 
use of heat and ice, weight loss, exercises, the use of physical 
support and occupational therapy and the removal of heaviness in 
joints such as the knees and hips (22).
Figure 4 – SYSADOA options for AO treatment among specialties
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Several of these interventions are part of physiotherapy treatment, 
which is divided among appropriated, uncertain and not appropriated 
treatment (23). This issue may be one reason why, in our query, when 
asked about the indication for physiotherapy as a global treatment, the 
physiatrists were less likely to prescribe physiotherapy at all stages.
For the treatment of knee OA, pharmacological 
recommendations from the American College of Rheumatology 
(ACR) include the use of acetaminophen, oral and topical NSAIDs, 
tramadol and articular injection of corticosteroids. The indication 
for surgery may be necessary when other treatments fail (22).
There are also the so-called “symptomatic slow-acting drugs 
in osteoarthritis” (SYSADOA), a description attributed to the fact 
that their effects, including the reduction in pain, require long-term 
administration to be noticeable (24). Among the drugs currently 
included in this category are chondroitin sulfate and chondroitin 
hydrochloride, glucosamine sulfate (24-26) and diacerein (27). 
When compared to NSAIDs, pain reduction and functional 
improvement are similar (24). However, considering tolerance and 
the reduced incidence of adverse effects and almost total absence of 
serious effects, SYSADOA have advantages over NSAIDs.
The last algorithm recommended for the management of knee 
OA elaborated by the European Study of Clinical and Economics 
Aspects of Osteoporosis and Osteoarthritis (ESCEO) (24-26,28,29) 
places “basic” pharmacological treatment using SYSADOA as 
the first step, more specifically the use of glucosamine with or 
without chondroitin. Our results showed that the combination of 
glucosamine and chondroitin is the most prescribed SYSADOA 
among the 3 categories, followed by isolated glucosamine, 
commonly prescribed by orthopedics and physiatrists.
The SAC drew attention to the fact that in general, clinical 
studies involve both chondroitin sulfate and chondroitin 
hydrochloride. This mixture of sulfate and hydrochloride can 
compromise clinical effects because sulfate is actually quite 
effective, unlike hydrochloride, whose results seem to contaminate 
the general findings (30).
The SAC data indicate that many patients, regardless of the site 
of OA, are largely not receiving any treatment, mainly those treated 
by orthopedists.
The SAC alerts to this fact and recommends that from the first 
clinical encounter, including the earliest stages of the disease, there 
be intervention as soon as the diagnosis is made because OA today 
is known as a disease that is liable to change. There are medicines 
capable of preventing and slowing the evolution of the disease. 
Prevention of the most advanced degrees of OA is of primary 
relevance. The inability to work and the reduction in quality of 
life greatly impacts the costs to the health and pension systems, 
whether in terms of treatment or in early retirement from functional 
disability (31).
The Delphi panel was instructed to report the current medical 
treatment in their respective regions, including the standards 
adopted for the treatment of patients with OA and not only 
individual experience. The panel relied on participants who 
were appointed by the scientific advisory committee, which was 
responsible for coordinating this research. Thus, it provided the 
best available evidence regarding the use of pharmacological and 
nonpharmacological options available for treatment. In addition, 
the Delphi panel received formal instruction on the application of 
the methodology. Therefore, the results presented herein reflect the 
consensual practice of the specialists in the treatment approaches 
for patients with symptomatic OA. These results are expected 
to be useful for the development of quality of life measures for 
OA patients. We also understand that new evidence is still being 
developed, which will be disseminated in future updates.
 ■ CONCLUSION
Osteoarthritis (OA) is a common form of joint disease, affecting 
33% of the Brazilian adult population. There is a large percentage 
of patients who do not receive any form of treatment in the earliest 
stages of the disease. The glucosamine + chondroitin combination 
is the most prescribed treatment by all three types of specialists, 
mainly in the initial phases of OA. The experience and different 
approaches of different types of specialists change the way of 
treating OA patients.
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